FAHD2A

Across TCGA pan-cancer cohorts, FAHD2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAHD2A data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAHD2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAHD2A expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where FAHD2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.857	0.673	.001	26	view →
LUAD	OS	Tertile	All	0.604	0.876	.005	4	view →
CCRCC	OS	Median	All	1.000	0.754	.034	1	view →
LSCC	DFS	Median	III,IV	0.867	1.000	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAHD2A–PDAC (DFS)

Open the PDAC breakdown →